tbuckley/cabot-search huggingface dataset:
Abstract A40: Six1 is dependent on its coactivator Eya2 to mediate tumor progression in the MCF7 mammary carcinoma cell line
Authors: Susan M. Farabaugh, Alana L. Welm, Heide L. Ford
Journal: Cancer Research (2009)

Abstract The homeobox transcription factor Six1 is a critical mediator of embryonic development. In adults, upregulation of Six1 has been associated with a number of cancers where it not only promotes proliferation and survival, contributing to tumorigenesis, but also upregulates the TGFβ pathway, brings about an EMT-like transformation, and promotes metastasis. The Eya coactivator family is critical for Six1-mediated transcriptional activation in development. Our research is aimed at identifying what role the Eya family plays in Six1-mediated breast cancer progression. Examination of publicly available microarray data sets revealed that although high levels of Six1 significantly correlates with a shortened time to metastasis in breast cancer patients, presence of the Eya1-Six1 or Eya2-Six1 transcriptional complex correlates with a further reduced time to metastasis as well as with a significant decrease in survival time in breast cancer patients. Utilizing Six1 overexpressing MCF7 breast carcinoma cells with stable knock down of Eya2, we have found that lack of Eya2 reverses Six1-induced upregulation of the TGFβ pathway. Additionally, most Six1-induced EMT properties, including increased β-catenin responsive transcription and increased levels of the mesenchymal marker Fibronectin, were reversed with loss of Eya2. Overall, these data implicate Eya2 as a critical coactivator that is necessary for most of the metastasis-associated properties induced by Six1. Thus, as Six1 and Eya are not normally expressed in most adult tissues, the Six1-Eya interaction may be a valuable future drug target whose inhibition should result in limited side effects while potently targeting the tumor and its associated metastases. Citation Information: Cancer Res 2009;69(23 Suppl):A40.
Spinal Cord Stimulation
Authors: Anthony F. DiMarco, Krzysztof E. Kowalski, Robert T. Geertman, Dana R. Hromyak
Journal: American Journal of Respiratory and Critical Care Medicine (2006)

Patients with spinal cord injury have an increased risk of developing respiratory tract infections as the result of expiratory muscle paralysis and consequent inability to cough. We have developed a method by which the expiratory muscles can be activated via lower thoracic and upper lumbar spinal cord stimulation to produce an effective cough mechanism. In a tetraplegic patient who required frequent (8.57+/-2.3 times per week [mean+/-SEM]) caregiver assistance to facilitate airway clearance and expectoration of secretions, three epidural electrodes were applied in the T9, T11, and L1 spinal cord regions. During stimulation at the T9 and L1 levels, airway pressures were 90 and 82 cm H2O, respectively. Peak expiratory flow rates were 6.4 L/s and 5.0 L/s; respectively. During combined (T9+L1) stimulation, airway pressure and expiratory flow rate increased to 132 cm H2O and 7.4 L/s, respectively. Addition of the third lead did not result in further increases in pressure generation. These values are characteristic of those observed with a normal subject. Because the patient is able to trigger the device independently, he no longer requires caregiver support for airway management. If confirmed in additional patients, spinal cord stimulation may be a useful method to restore an effective cough mechanism in patients with spinal cord injury.
Recent record of the U.K. to publication in top dermatology journals
Authors: J.L. Rees, Y. Bisset
Journal: British Journal of Dermatology (2006)

British Journal of DermatologyVolume 154, Issue 5 p. 1016-1016 Recent record of the U.K. to publication in top dermatology journals J.L. Rees, J.L. Rees Department of Dermatology, The University of Edinburgh, Lauriston Place, Edinburgh EH3 9HA, U.K. E-mail: jonathan.rees@ed.ac.ukSearch for more papers by this authorY. Bisset, Y. Bisset Department of Dermatology, The University of Edinburgh, Lauriston Place, Edinburgh EH3 9HA, U.K. E-mail: jonathan.rees@ed.ac.ukSearch for more papers by this author J.L. Rees, J.L. Rees Department of Dermatology, The University of Edinburgh, Lauriston Place, Edinburgh EH3 9HA, U.K. E-mail: jonathan.rees@ed.ac.ukSearch for more papers by this authorY. Bisset, Y. Bisset Department of Dermatology, The University of Edinburgh, Lauriston Place, Edinburgh EH3 9HA, U.K. E-mail: jonathan.rees@ed.ac.ukSearch for more papers by this author First published: 24 March 2006 https://doi.org/10.1111/j.1365-2133.2006.07221.xCitations: 2 Conflicts of interest: none declared. Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinked InRedditWechat No abstract is available for this article.Citing Literature Volume154, Issue5May 2006Pages 1016-1016 RelatedInformation
Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options
Authors: Yoshiyuki Suzuki, Kenji Ikeda, Fumitaka Suzuki, Joji Toyota, Yoshiyasu Karino, Kazuaki Chayama, Yoshiiku Kawakami, Hiroki Ishikawa, Hideaki Watanabe, Wenhua Hu, Timothy Eley, Fiona McPhee, Eric Hughes, Hiromitsu Kumada
Journal: Journal of Hepatology (2012)
(21) Dermatitis herpetiformis with tongue lesions
Authors: G.C. Muston, G.A. Hodgson
Journal: British Journal of Dermatology (1973)

Journal Article (21) Dermatitis herpetiformis with tongue lesions Get access G.C. Muston, G.C. Muston Department of Dermatology, University Hospital of Wales, Cardiff Search for other works by this author on: Oxford Academic Google Scholar G.A. Hodgson G.A. Hodgson Department of Dermatology, University Hospital of Wales, Cardiff Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 89, Issue s9, 1 July 1973, Pages 85–88, https://doi.org/10.1111/j.1365-2133.1973.tb03454.x Published: 01 July 1973
Whatever Became of Chlorosis?
Authors: William H. Crosby
Journal: JAMA (1987)

THE FIRST perennial index of medical literature commenced publication in 1880. That volume included all the A's and some<i>B</i>'s. The second volume of the<i>Index Catalog of the Library of the Surgeon General's Office U.S. Army</i>, containing<i>Berlioz-Cholas</i>, appeared in 1881. The second volume, heftier than any single volume of today's<i>Index Medicus</i>, contains more than seven pages of references to "chlorosis." One hundred years later, in 1981,<i>Index Medicus</i>contains none, not one, no listing at all. Chlorosis is gone from<i>Index Medicus</i>because it is gone from the practice of medicine. In 1881, chlorosis was a common disease, an iron deficiency anemia appearing especially in maturing girls during the adolescent growth spurt; it was less common in mature women and rare in men. It was called chlorosis because the victims were pale green, pale because anemic, green—who knows why? Hippocrates mentioned the greensickness. Shakespeare made a
Vitamin K Supplementation in Postmenopausal Women with Osteopenia (ECKO Trial): A Randomized Controlled Trial
Authors: Angela M Cheung, Lianne Tile, Yuna Lee, George Tomlinson, Gillian Hawker, Judy Scher, Hanxian Hu, Reinhold Vieth, Lilian Thompson, Sophie Jamal, Robert Josse
Journal: PLoS Medicine (2008)

Vitamin K has been widely promoted as a supplement for decreasing bone loss in postmenopausal women, but the long-term benefits and potential harms are unknown. This study was conducted to determine whether daily high-dose vitamin K1 supplementation safely reduces bone loss, bone turnover, and fractures.
Learn from banking crisis and stamp out competition in the NHS, says BMA chairman
Authors: Z. Kmietowicz
Journal: BMJ (2009)

The head of the BMA has called on the government to “end its obsession” with the market to avoid a crisis in the health service similar to that seen in the banking sector in the past few months.

Hamish Meldrum, the chairman of the BMA, said the meltdown in the city should have “sent alarm bells ringing in the department of health,” adding that “relying on …
High titers of inhibitors of von Willebrand factor-cleaving metalloproteinase in a fatal case of acute thrombotic thrombocytopenic purpura
Authors: Han-Mou Tsai
Journal: American Journal of Hematology (2000)

Acute thrombotic thrombocytopenic purpura is a disease with diffuse platelet thrombi in the microcirculation. Despite plasma exchange therapy, approximately 20 percent of the patients succumb to the disease. A significant number of the survivors suffer one or more relapses. This study investigated the activity of von Willebrand factor-cleaving metalloproteinase and the titers of IgG inhibitors to the proteinase in serial plasma samples from a patient who died during a relapse of the disease despite continued plasma exchanges. A deficiency in the von Willebrand factor-cleaving metalloproteinase activity, due to inhibitory IgG, was detected at presentation. After initiation of plasma exchange, a transient increase in proteinase activity coincided with clinical remission. When thrombocytopenia relapsed, the activity of the proteinase also declined to undetectable levels. Toward the end of her course, proteinase levels raised by plasma exchange were not sustained because the proteinase activity was quickly neutralized by rising titers of inhibitors. High titers of inhibitors of von Willebrand factor-cleaving metalloproteinase cause refractoriness to standard plasma therapy. These findings suggest that intensive plasma exchanges and measures that suppress antibody titers may prevent death and promote remission in refractory cases. Am. J. Hematol. 65:251–255, 2000. © 2000 Wiley-Liss Inc.
No Refuge for the Ailing
Authors: Ranjana Srivastava
Journal: New England Journal of Medicine (2006)

The still, oppressive heat of the afternoon seems to magnify the queue of waiting patients. A young woman separates herself from the crowd.“Excuse me, Doctor, how long will you be?”I answer with a flicker of annoyance, “I am not sure, but I will see you.”An hour later, it is her turn. She looks far too well, I silently judge. The well worried. She springs from her seat at the sound of her name but moves away from me toward the stairs. There, she utters a rapid command in a foreign tongue before turning apologetically toward me. Before . . .
Amphetamine, mazindol, and fencamfamin in narcolepsy.
Authors: J Shindler, M Schachter, S Brincat, J D Parkes
Journal: BMJ (1985)

Twenty patients with the narcoleptic syndrome were treated separately with dexamphetamine sulphate tablets 10 and 30 mg, Dexedrine Spansules 10 mg, mazindol 4 mg, and fencamfamin hydrochloride 60 mg daily. Each drug was given for four weeks and the effects compared. In these dosages the reported frequency of attacks of narcolepsy was roughly halved with each treatment, dexamphetamine 30 mg daily being only slightly more potent than 10 mg. The subjective effects of Dexedrine tablets and Spansules could not be distinguished by most patients. Effects on mood, alertness, and sympathomimetic side effects were largely inseparable with all these drugs, but a decrease in appetite was not reported by patients with narcolepsy.
Acute pancreatitis: The acute attack. Acute recurrent pancreatitis
Authors: S. Seewald, S. Omar, N. Soehendra
Journal: Endoscopy (2006)

Due to the well accessibility of the pancreatobilary system, the potential role of EUS and EUS-FNA in an acute attack of a first episode or recurrent idiopathic pancreatitis seems to be an issue. Since EUS is competing with other imaging modalities such as CT, MRCP and ERCP, the following questions have to be raised. (1) Is there a role for EUS as one of the initial imaging modalities? (2) Can EUS replace other diagnostic procedures, especially ERCP? (3) In which period of the acute attack may EUS and EUS-FNA play a role?
WHO faces up to its tobacco links
Authors: F. Godlee
Journal: BMJ (2000)

Five years ago I wrote a critique of the World Health Organization in the BMJ .1 One of my sources was a report by an American economist, Richard Tollison, which tore apart the WHO's budgetary priorities. Tollison's main claim was that too little of the WHO's money was spent on improving health in the developing world.2 One statement quoted in the BMJ ran, “The poorest nations in WHO are interested in basic public health, and not in the more exotic forays of WHO into the public health issues of the modern industrialised West.”3 What I and the BMJ and its readers didn't know, because the report didn't say, was that Tollison was in the pay of British American Tobacco. Nor did we know that such covert funding of “independent” commentators was just one part of an elaborate campaign by the tobacco industry to discredit the WHO and divert money and attention away from tobacco control activities.

The WHO has been concerned for some time about the poor success of its anti-tobacco initiatives. The forced disclosure last year of 35 million pages of confidential tobacco industry documents alerted the WHO to the possibility of direct interference and led its director general, Dr Gro Harlem Brundtland, to set …
Incidence and Predictors of Implantable Cardioverter-Defibrillator Therapy in Patients With Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy Undergoing Implantable Cardioverter-Defibrillator Implantation for Primary Prevention
Authors: Aditya Bhonsale, Cynthia A. James, Crystal Tichnell, Brittney Murray, Dmitri Gagarin, Binu Philips, Darshan Dalal, Ryan Tedford, Stuart D. Russell, Theodore Abraham, Harikrishna Tandri, Daniel P. Judge, Hugh Calkins
Journal: Journal of the American College of Cardiology (2011)
Neonatal service reorganisation fails to iron out regional variation in death rates
Authors: Owen Dyer
Journal: BMJ (2008)

Five years after a major reorganisation of England's neonatal services, large and unexplained variations between regions in mortality among neonates still exist, concludes a new report from the House of Commons Public Accounts Committee.England's 178 neonatal care units were ordered in 2003 to reorganise into 23 regional networks.But that reorganisation has failed to address discrepancies between regions; and two regions, Essex and the Northern, have still not formally merged into unified organisations after five years.In 2005 the neonatal mortality rate among babies born at more than 22 weeks' gestation varied from 1.8 deaths per 1000 live births in the Surrey and Sussex region to 4.8 in the South West Midlands.The Conservative MP Edward Leigh, who chairs the Public Accounts Committee, said that the 2003 reorganisation "has had limited effect in reducing regional variations in mortality rates of babies born prematurely or suffering an illness [and] needing specialist care."The Department of Health was unable to confirm whether these discrepancies were due to disparities in care or to demographic factors, he said.Primary care trusts, Mr Leigh added, "need to improve their understanding of the Reorganisation of neonatal service in England fails to iron out regional variation in death rates UK NEWS Regulation of alternative medicine faces more delays, p 1395 WoRld NEWS dutch doctors make advice on suicide available to public, p 1394 bmj.com Germany promises protection to hospital doctors over longer working hours
Percutaneous Suprasternal Puncture (Radner Technique) of the Pulmonary Artery in Transposition of the Great Vessels
Authors: SHAHBUDIN H. RAHIMTOOLA, PATRICK A. ONGLEY, H. J. C. SWAN
Journal: Circulation (1966)

Introduction of a cardiac catheter into the pulmonary artery from the right heart is not possible in a substantial proportion of patients with transposition of the great vessels. It is necessary to obtain the pulmonary artery pressure and oxygen saturation value to evaluate the degree of pulmonary stenosis and the pulmonary vascular resistance. Twenty-three patients are described in whom this was accomplished by percutaneous suprasternal puncture. There was no mortality and there were no significant complications. The technique appears to be safe and reliable.
The starving of the medical schools.
Authors: R Smith
Journal: BMJ (1982)

Aberdeen Birmingham Dundee London University of Wales Bristol Liverpool Manchester Leeds Nottingham Sheffield Newcastle Oxford Southampton Edinburgh Glasgow Cambridge Leicester 1975 30-81 12 64 200 57-2 2305 3118 38-2 3393 21-39 25-4 23-97 340 18-91 30-81 3368 3227 13 12 17-24 27-83 11 41 18102 51-85 20-91 28-21 3453 30-86 1949 23-25 22-03 31-33 17-47 31-50 30-76 3003 12-29 15 19 25-69 1053 16503 47-67 19-43 2613 31 93 28-72 18-36 21-72 20-85 29-74 166 30-2 2956 28-91 11-95 23 17 17 17 17 16 16 16 15 14 14 13 13 12 11 11 10 9 60 41 4-2 65 4 6 3-4 33 4-2 5-8 6-2 4-7 4-8 135 5 1 61 6 1 8-9 4-7
Abstract 1363: Inhibition of Neuropilin-1 by anti-Nrp1 results in reduced angiogenesis and inhibition of tumor growth
Authors: Judy Mak, Qi Pan, Leanne Berry, Sarajane Ross, Hartmut Koeppen, Plowman Greg, Ryan Watts, Anil Bagri
Journal: Cancer Research (2010)

Abstract Neuropilin-1 (NRP1) guides the development of the nervous and vascular systems and has been implicated in modulating various aspects of tumor cell function. We have previously shown that an antibody directed against NRP1 inhibits tumor growth and reduces tumor angiogenesis, as a single agent and more potently in combination with anti-VEGF. However, as NRP1 was also expressed in the tumor cells tested, the impact from inhibiting tumor cell NRP1 in these experiments was unclear. The objective of this study was to determine if inhibition of tumor cell NRP1 was necessary for the observed anti-tumor effects previously described for anti-NRP1. We tested the effects of anti-NRP1 in tumor lines that do not express NRP1, and where expression of NRP1 is restricted to the vasculature. Inhibition of tumor growth as a single agent, and in combination with anti-VEGF in these xenografted tumor lines, confirm that tumor expression of NRP1 is not necessary for the anti-tumor effects of anti-NRP1. We furthermore demonstrate that anti-NRP1 treatment of endothelial cells in in vitro sprouting assays results in potent inhibition of vascular sprout formation, confirming its anti-angiogenic activity. In vivo, in developmental models of angiogenesis, treatment results in reduced angiogenesis that is augmented by anti-VEGF. Finally, we demonstrate that treatment of primates with anti-NRP1 results in up-regulation of cytokines, such as PlGF, that are commonly increased with anti-angiogenic agent treatment. In total, these data confirm that anti-NRP1 mechanistically acts to inhibit tumor angiogenesis, thus resulting in reduced tumor growth and this tumor inhibition is most effective in combination with VEGF inhibition. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 1363.
Scotland considers screening patients on admission to hospital to cut infections
Authors: Bryan Christie
Journal: BMJ (2007)

Scotland is considering screening patients for methicillin resistant Staphylococcus aureus (MRSA) when they are admitted to hospital, to help reduce the incidence of healthcare associated infections.

The move comes after the completion of a comprehensive study of the prevalence of such infections in Scotland, which found that 9.5% of patients contract an infection while in Scottish hospitals. The annual cost is calculated to be £183m (€270m; $370m).

The study, carried out by Health Protection Scotland, was based on a survey of almost 14 000 patients—the entire acute hospital population at the time of the survey …
Anaemia in the Tropics
Authors: E. J. Watson-Williams
Journal: BMJ (1968)

Anaemia is one of the commonest manifestations of ill-health in the tropics. The causes are numerous, and anaemia in most patients is contributed to by several independent and inter dependent factors. Moreover, the importance of different nutri tional, environmental, and genetic factors differs widely from area to area. It is impossible, therefore, to give a detailed review of the diagnosis and management of anaemia in a brief article. Instead I have attempted to describe how the practi tioner with limited resources may assess the different factors responsible for anaemia and plan rational management of his patients.
A micropuncture study of renal phosphate transport in rats with chronic renal failure and secondary hyperparathyroidism.
Authors: N Bank, W S Su, H S Aynedjian
Journal: Journal of Clinical Investigation (1978)

Micropuncture studies were carried out in rats to determine changes in tubular transport of phosphate which occur in chronic renal failure and secondary hyperparathyroidism. Rats underwent subtotal nephrectomy (NX) and were fed a low calcium, high phosphorus diet for 3--4 wk. Other groups consisted of normal control animals, normal rats infused with sodium phosphate to raise filtered load of phosphate, subtotal NX rats parathyroidectomized (PTX) on the day of experiment, and normal PTX rats infused with sodium phosphate. It was found that filtered phosphate/nephron is markedly increased in subtotal NX rats due to high single nephron filtration rates, proximal tubular fluid plasma phosphate ratios are less than 1.0, and fractional reabsorption of phosphate is decreased in the proximal tubule. More phosphate was present in the final urine than in surface distal convoluted tubules. Acute PTX in subtotal NX rats resulted in a striking increase in proximal phosphate reabsorption, and urinary phosphate became approximately equal to that remaining in surface distal tubules. Phosphate loading in normal rats reduced fractional reabsorption in the proximal tubule, but urinary phosphate was not greater than that at the end of surface distal tubules. Acute PTX in normal phosphate-loaded animals had no significant effect on proximal tubular phosphate reabsorption. These observations suggest that phosphate homeostasis in chronic renal failure is acheived by inhibition of proximal phosphate reabsorption, counteracting a greatly enhanced intrinsic capacity for reabsorption. In addition, the large amount of urinary phosphate is consistent either with secretion by the collecting ducts or with a disproportionately high contribution by deep nephrons. The changes in phosphate transport are mediated by parathyroid hormone and are completely abolished by acute removal of the hormone.
Calculation of Cardiac Output from Indicator-Dilution Curves in the Presence of Mitral Regurgitation
Authors: SHAHBUDIN H. RAHIMTOOLA, H. J. C. SWAN
Journal: Circulation (1965)

Cardiac output was determined by the indicator-dilution technic with injection of indicator into the ascending aorta, left ventricle, and pulmonary artery in 13 cases of mitral incompetence and in 15 control cases (normal or mild valvular obstruction). The ascending aortic dye curve is not involved in mitral incompetence in its primary circulation and was used for comparison. In normal subjects, there is no significant difference between the cardiac output obtained by injection of indicator into the ascending aorta and the left ventricle. The cardiac output obtained from indicator-dilution curves affected by mitral regurgitation in its primary circulation is underestimated by approximately 20 per cent. The effects of the coronary recirculated indicator particles on the disappearance slope would best explain the discrepancy. Even in the normal circulation, the inclusion of the coronary recirculated particles leads to a small underestimation of the cardiac output when the indicator is injected into the pulmonary artery.